The clinical relevance of molecular diagnosis in children allergic to grass pollen and treated with allergen immunotherapy

2019 ◽  
Vol 47 (3) ◽  
pp. 309-310
Author(s):  
S. Barberi ◽  
G. Traina ◽  
M. Landi ◽  
G. De Castro ◽  
D. Peroni ◽  
...  
Alergologia ◽  
2020 ◽  
Vol 1 (4) ◽  
pp. 10
Author(s):  
Maria Roxana Buzan ◽  
Manuela Grijincu ◽  
Lauriana-Eunice Zbîrcea ◽  
Laura Haidar ◽  
Carmen Bunu-Panaitescu

2016 ◽  
Vol 63 (2) ◽  
pp. 178-182
Author(s):  
Georgeta Sinitchi ◽  
◽  
Aurica Rugina ◽  
Smaranda Diaconescu ◽  
◽  
...  

Introduction. Specific allergen immunotherapy (STI) is the causal treatment of asthma. SIT gives a specific response to the changing LT response (deviation of the immune response), induction of anergy (decrease of LTh2), induces tolerance and modifies the inflammatory response. Pollen produces in our country seasonal allergic asthma in children and adults. Materials and methods. Our study was conducted using grass pollen extracts and comprised a total of 47 children with asthma, allergic to pollens, aged 5-14. Administration was seasonal (November to April), oral (sublingual solutions). It was indicated in the treatment of children with asthma and rhinitis with definite diagnosis where eviction was not possible. There have been previously detailed history and a careful clinical examination, skin prick tests to pollens with intense response, more elevated IgE, and spirometry confirming bronchospasm. Grass pollen extracts with initial low doses were used, gradually increasing the amount and concentration, and a gradual decrease, at a total of 6 months per year, with a duration of three years. Discussion. The evaluation was performed by clinical follow-up (symptom score and drug consumption), spirometry and by improving the quality of life assessment. There were no serious side effects during treatment. Conclusion. SIT in children with pollens allergic asthma is the causal therapeutic method; treating asthmatic children over 3 years old; reduces asthma symptoms to extinction; decreases other medical needs; improves quality of life of the child; no side effect were distinguished.


Immunotherapy ◽  
2019 ◽  
Vol 11 (18) ◽  
pp. 1569-1582
Author(s):  
Vera Mahler ◽  
Stefan Zielen ◽  
Martin Rosewich

Aim: Allergen immunotherapy (AIT) is an effective treatment for allergic diseases. We investigate whether treatment-initiation during the pollen season is safe. Methods: RCT-IIIb-trial of 6-grass-pollen-allergoid (Allergovit®) in grass pollen-allergic patients (18–65 years) with moderate–severe rhinitis/rhinoconjunctivitis (± controlled asthma), randomized 2:1 to treatment-initiation during (Group-A) versus outside the pollen season (Group-B). Results: Of 240 patients (32.8 ± 9.9 years, 19.5% asthma) treated, 84.9% (Group-A) and 86.6% (Group-B) reached maintenance dose without delay. Treatment-emergent adverse events occurred in 108 (68.4%/Group-A) and 41 patients (56.2%/Group-B) leading to premature trial-termination in 11 patients (7%/A) versus 3 (4.1%/B). Across groups, physicians (for 190 patients; 85.2%) and patients (192; 86.1%) rated the tolerability as ‘very good’–‘good’. Phleum pratense-specific IgG4 increased in both groups (p < 0.0001). Conclusion: Year-round allergen immunotherapy-initiation with this preparation is safe.


Sign in / Sign up

Export Citation Format

Share Document